As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

Mutual of America Capital Management LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.6% during the ...

The top executives of Moderna, Akamai, and FMC just bought stock on the open market. All three shares are in the red for 2025 ...

A mobile research unit will be travelling to some of the remotest parts of Cornwall as part of the trial to find a vaccine for the winter ...

The Florida surgeon general in January called for a halt in the use of covid mRNA vaccines. And in Texas, Attorney General ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) saw unusually large options trading activity on Thursday. Stock investors purchased 143,752 call options on the company. This represents an increase of ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

NIH technology transfer offices have been barred from filing new patent applications and restricted from licensing existing ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

The leader of an iconic apparel company and the co-founder and chair of Moderna are the honored speakers for the Worcester ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...